Sign up to save your podcasts
Or
Share The Beacon
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Beacon
The Beacon episodes
- Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Should It Become Standard of Care Without Overall Survival Benefit Demonstrated? (BMIC-024)
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of care after concurrent chemoradiation.
8 min - A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC.
9 min - Chemo-Immunotherapy in Non-Squamous NSCLC: Has the KEYNOTE-189 Trial Defined a Clear Standard of Care? (BMIC-022)
Dr. Jack West reviews the results and pending questions of the KEYNOTE-189 trial of chemotherapy with or without pembrolizumab (KEYTRUDA) as first line therapy for advanced non-squamous NSCLC, as well as how they change the treatment landscape.
7 min - T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021)
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed strongest benefit of atezo in those with T effector gene signature high expression or high PD-L1.
11 min - Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune checkpoint inhibitor atezolizumab to carbo/paclitaxel/bevacizumab in patients with chemo-naïve advanced non-squamous NSCLC.
12 min - Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019)
Dr. Jack West reviews the implications, both encouraging and potentially detrimental, of a recent FDA approval for broad genomic (NGS) testing of all solid tumors, ushering in a new era of growing precision medicine and molecular oncology.
10 min - New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018)
Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Planchard & colleagues in Lancet Oncology.
7 min - Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017)
Dr. Jack West reviews the pros and cons of using osimertinib first line vs. "saving" it as a second line therapy, trying to determine the optimal sequence for EGFR-directed therapy in advanced EGFR mutation-positive NSCLC.
12 min - Dacomitinib: Dark Horse EGFR TKI Charges into a Crowded First Line Setting for EGFR Mutation-Positive Advanced NSCLC (BMIC-016)
Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting?
9 min - Are the PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeable in Lung Cancer Management? (BMIC-015)
Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management can be viewed as a class effect and whether these immune checkpoint inhibitors should be considered interchangeable.
7 min
About The Beacon
From the publisher's feed
Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.